ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2025-01-15
Target enrollment:
Participant gender:
Summary
Endometrial cancer (EC) is the fourth most common cancer in United States women, and
alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity
epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as
compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to
be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard
first-line treatment), radiation, or a combination of these. Thus, new treatments for EC are
desperately needed as well as a better understanding of the impact of obesity on EC biology
and treatment.
The purpose of this study is to test the safety of a combination of treatments, atezolizumab
and ONC201, given based on body weight, to treat endometrial cancer. Using the combination of
atezolizumab and ONC201, has not been approved by the Food and Drug Administration (FDA) for
the treatment of endometrial cancer. This clinical trial will examine the treatment of
atezolizumab + ONC201 in obese and non-obese subjects with metastatic/recurrent EC.